Black and Hispanic Patients are More Likely to be Treated with Disease Modifying Therapies for Multiple Sclerosis than White patients: Medicare Analysis 2014-2016

被引：0
|
作者：
Xu, L. [1 ]
Williams, M. [2 ]
Amezcua, L. [3 ]
Vignos, M. [4 ]
Gamba, J. [4 ]
Puckrein, G. [1 ]
机构：
[1] Natl Minor Qual Forum, Washington, DC USA
[2] Multiple Sclerosis Ctr Atlanta, Atlanta, GA USA
[3] Keck Sch Med, Dept Neurol, Los Angeles, CA USA
[4] Biogen, Cambridge, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P326
引用
收藏
页码：169 / 169
页数：1
相关论文
共 50 条
  • [21] Pregnancy Outcome in Multiple Sclerosis Patients Exposed to Disease Modifying Therapies
    Ahmed, Samar Farouk
    Almuteri, Manal L.
    Al-Hashel, Jasem
    Alroughani, Raed
    NEUROLOGY, 2019, 92 (15)
  • [22] Disease modifying therapies prevent secondary progression in multiple sclerosis patients
    Bergamaschi, Roberto
    Amato, Maria Pia
    Quaglini, Silvana
    Tavazzi, Eleonora
    Paolicelli, Damiano
    Portaccio, Emilio
    Troiano, Maria
    MULTIPLE SCLEROSIS, 2008, 14 : S32 - S32
  • [23] The evaluation of disease modifying therapies for side effects in patients with multiple sclerosis
    Agaoglu, J.
    Kale, N.
    Onder, G.
    Emir, C.
    Tanik, O.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 240 - 240
  • [24] Factors Influencing Patients' Choices of Disease Modifying Therapies in Multiple Sclerosis
    Sharrack, Basil
    Elias, Reem
    Reuber, Markus
    NEUROLOGY, 2012, 78
  • [25] Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies
    Elena Grebenciucova
    Amy Pruitt
    Current Neurology and Neuroscience Reports, 2017, 17
  • [26] Persistence to oral disease-modifying therapies in multiple sclerosis patients
    Lattanzi, Simona
    Danni, Maura
    Taffi, Ruja
    Cerqua, Raffaella
    Carlini, Giulia
    Pulcini, Alessandra
    Provinciali, Leandro
    Silvestrini, Mauro
    JOURNAL OF NEUROLOGY, 2017, 264 (11) : 2325 - 2329
  • [27] Switching disease-modifying therapies in multiple sclerosis patients: A study on 110 patients
    Morra, V. Brescia
    Coppola, G.
    Vacca, G.
    Longobardi, M.
    Ascione, S.
    Schiavone, V.
    Pagano, A.
    Bonavita, V.
    Orefice, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 263 - 264
  • [28] The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement
    Moiola, Lucia
    Barcella, Valeria
    Benatti, Simone
    Capobianco, Marco
    Capra, Ruggero
    Cinque, Paola
    Comi, Giancarlo
    Fasolo, Maria Michela
    Franzetti, Fabio
    Galli, Massimo
    Gerevini, Simonetta
    Meroni, Luca
    Origoni, Massimo
    Prosperini, Luca
    Puoti, Massimo
    Scarpazza, Cristina
    Tortorella, Carla
    Zaffaroni, Mauro
    Riva, Agostino
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (03) : 331 - 346
  • [29] Cognitive functions over the course of 5 years in multiple sclerosis patients treated with disease modifying therapies
    Ozakbas, S.
    Baba, C.
    Aslan, T.
    Sagici, O.
    Simsek, Y.
    Yigit, P.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 877 - 877
  • [30] Cognitive functions over the course of 1 year in multiple sclerosis patients treated with disease modifying therapies
    Lee, Kathrin S. Utz De-Hyung
    Laemmer, Alexandra
    Waschbisch, Anne
    Linker, Ralf A.
    Schenk, Thomas
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (04) : 269 - 280
12345